The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
As the GLP-1 gold rush enters its most aggressive phase,
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
Pfizer has rejoined the weight-loss race with a $4.9bn move
Metsera’s Weight-Loss Drug MET-097i Shows Strong Clinical Results
Obesity remains a critical public health challenge in the United
MOST POPULAR
